Hypoglycemic Agents
"Hypoglycemic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances which lower blood glucose levels.
Descriptor ID |
D007004
|
MeSH Number(s) |
D27.505.696.422
|
Concept/Terms |
Hypoglycemic Agents- Hypoglycemic Agents
- Agents, Hypoglycemic
- Hypoglycemics
- Hypoglycemic Drugs
- Drugs, Hypoglycemic
- Antihyperglycemic Agents
- Agents, Antihyperglycemic
- Antihyperglycemics
Hypoglycemic Effect- Hypoglycemic Effect
- Effect, Hypoglycemic
- Hypoglycemic Effects
- Effects, Hypoglycemic
Antidiabetics- Antidiabetics
- Antidiabetic Drugs
- Drugs, Antidiabetic
- Antidiabetic Agents
- Agents, Antidiabetic
|
Below are MeSH descriptors whose meaning is more general than "Hypoglycemic Agents".
Below are MeSH descriptors whose meaning is more specific than "Hypoglycemic Agents".
This graph shows the total number of publications written about "Hypoglycemic Agents" by people in this website by year, and whether "Hypoglycemic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
1991 | 1 | 0 | 1 | 1995 | 1 | 1 | 2 | 1996 | 1 | 0 | 1 | 1997 | 3 | 4 | 7 | 1998 | 2 | 3 | 5 | 1999 | 0 | 2 | 2 | 2000 | 4 | 3 | 7 | 2001 | 1 | 3 | 4 | 2002 | 4 | 2 | 6 | 2003 | 4 | 2 | 6 | 2004 | 5 | 4 | 9 | 2005 | 5 | 3 | 8 | 2006 | 7 | 4 | 11 | 2007 | 4 | 6 | 10 | 2008 | 6 | 3 | 9 | 2009 | 4 | 7 | 11 | 2010 | 6 | 6 | 12 | 2011 | 4 | 5 | 9 | 2012 | 3 | 4 | 7 | 2013 | 10 | 8 | 18 | 2014 | 11 | 8 | 19 | 2015 | 13 | 5 | 18 | 2016 | 9 | 7 | 16 | 2017 | 11 | 6 | 17 | 2018 | 6 | 11 | 17 | 2019 | 6 | 8 | 14 | 2020 | 2 | 3 | 5 |
To return to the timeline, click here.
Below are the most recent publications written about "Hypoglycemic Agents" by people in Profiles.
-
Leung MST, Lin SG, Uthayanan L, Harky A. Effects of antidiabetic medications on cardiovascular outcomes. J Card Surg. 2020 Oct; 35(10):2759-2767.
-
Elharram M, Sharma A, White W, Bakris G, Rossignol P, Mehta C, Ferreira JP, Zannad F. Timing of randomization after an acute coronary syndrome in patients with type 2 diabetes mellitus. Am Heart J. 2020 11; 229:40-51.
-
Dude AM, Niznik C, Peaceman AM, Yee LM. Evaluation of an Intrapartum Insulin Regimen for Women With Diabetes. Obstet Gynecol. 2020 08; 136(2):411-416.
-
Pratley RE, Kanapka LG, Rickels MR, Ahmann A, Aleppo G, Beck R, Bhargava A, Bode BW, Carlson A, Chaytor NS, Fox DS, Goland R, Hirsch IB, Kruger D, Kudva YC, Levy C, McGill JB, Peters A, Philipson L, Philis-Tsimikas A, Pop-Busui R, Shah VN, Thompson M, Vendrame F, Verdejo A, Weinstock RS, Young L, Miller KM. Effect of Continuous Glucose Monitoring on Hypoglycemia in Older Adults With Type 1 Diabetes: A Randomized Clinical Trial. JAMA. 2020 06 16; 323(23):2397-2406.
-
Philipson LH. Harnessing heterogeneity in type 2 diabetes mellitus. Nat Rev Endocrinol. 2020 02; 16(2):79-80.
-
Hart PC, Kenny HA, Grassl N, Watters KM, Litchfield LM, Coscia F, Blaženovic I, Ploetzky L, Fiehn O, Mann M, Lengyel E, Romero IL. Mesothelial Cell HIF1a Expression Is Metabolically Downregulated by Metformin to Prevent Oncogenic Tumor-Stromal Crosstalk. Cell Rep. 2019 12 17; 29(12):4086-4098.e6.
-
Baghikar S, Benitez A, Fernandez Piñeros P, Gao Y, Baig AA. Factors Impacting Adherence to Diabetes Medication Among Urban, Low Income Mexican-Americans with Diabetes. J Immigr Minor Health. 2019 Dec; 21(6):1334-1341.
-
Cannon CP, Perkovic V, Agarwal R, Baldassarre J, Bakris G, Charytan DM, de Zeeuw D, Edwards R, Greene T, Heerspink HJL, Jardine MJ, Levin A, Li JW, Neal B, Pollock C, Wheeler DC, Zhang H, Zinman B, Mahaffey KW. Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c <7%: Results From the CREDENCE Trial. Circulation. 2020 02 04; 141(5):407-410.
-
Theobald J, Schneider J, Cheema N, DesLauriers C. Time to development of metformin-associated lactic acidosis. Clin Toxicol (Phila). 2020 07; 58(7):758-762.
-
Bakris G. Chronic Kidney Disease in Type 2 Diabetes: Optimizing Glucose-Lowering Therapy. J Fam Pract. 2019 10; 68(8):S1-S6.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|